During Q4 2018 the big money sentiment increased to 1.07. That’s change of 0.10, from 2018Q3’s 0.97. 25 investors sold all, 36 reduced holdings as Ironwood Pharmaceuticals, Inc. ratio increased. 39 rose stakes while 26 funds acquired stakes. Funds hold 140.64 million shares thus 1.17% less from 2018Q3’s 142.30 million shares.
Smith Asset Mngmt Grp Inc Limited Partnership invested 0.01% in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Northern Trust, a Illinois-based fund reported 1.71 million shs. Balyasny Asset Ltd holds 29,207 shs or 0% of its capital. Canada Pension Plan Investment Board owns 397,200 shs for 0.01% of their capital. Art Advisors Limited Liability Corp reported 84,869 shs. Granahan Inv Incorporated Ma, Massachusetts-based fund reported 395,574 shs. Cwm Ltd Liability Corporation accumulated 2,974 shs. Amer Grp Incorporated holds 0% or 92,618 shs in its capital. Moreover, Orbimed Advsr Limited Liability has 0.55% invested in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Moody National Bank Division reported 419 shs or 0% of all its holdings. Ameritas Investment Prtnrs holds 11,821 shs. 610,753 were accumulated by Bankshares Of New York Mellon. 12,032 were reported by Jefferies Gru Lc. Adage Capital Prns Gp Limited Co invested in 1.88M shs. Ecor1 Cap Ltd Llc has invested 5.58% in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD).

Ironwood Pharmaceuticals, Inc. had 4 insider sales and 0 insider buys since November 9, 2018. This’s net activity of $1.18 million. Hecht Peter M sold $1.12 million worth of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) on Wednesday, January 23. The insider OLANOFF LAWRENCE S sold 2,000 shs worth $24,940. On Thursday, December 6 a trade for 1,500 shs valued at $18,690 was made by McHugh Julie.

On May, 7 WallStreet anticipated Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)’s earnings release, as reported by RTT. EPS of $-0.12 is 55.56 % up from 2018’s $-0.27 EPS. After $-0.02 EPS report previous quarter, Wall Street now predicts 500.00 % negative EPS growth of Ironwood Pharmaceuticals, Inc.. The stock increased 1.82% or $0.23 during the last trading session, hitting $12.89.Currently Ironwood Pharmaceuticals, Inc. is downtrending after 2.58% change in last April 6, 2018. IRWD has 1.21M shares volume. IRWD underperformed by 6.95% the S&P500.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Ratings Coverage

Total analysts of 5 have positions in Ironwood Pharmaceuticals (NASDAQ:IRWD) as follows: 1 rated it a “Buy”, 0 with “Sell” and 4 with “Hold”. The positive are 20%. Since November 7, 2018 according to StockzIntelligence Inc Ironwood Pharmaceuticals has 8 analyst reports. On Wednesday, November 7 the stock has “Neutral” rating by Credit Suisse. In Thursday, January 24 report JP Morgan upgraded it to “Neutral” rating and $13 target. On Friday, February 22 the firm earned “Buy” rating by Mizuho. On Friday, March 22 the rating was maintained by Credit Suisse with “Hold”. On Wednesday, November 7 the rating was downgraded by JP Morgan to “Underweight”. On Wednesday, March 27 the firm has “Equal-Weight” rating given by Morgan Stanley. On Monday, February 25 the company was upgraded by H.C. Wainwright.

Ironwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products.The company has $1.99 billion market cap. The firm markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States and Constella name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout under ZURAMPIC and DUZALLO names.Last it reported negative earnings. It has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in North America, China, Hong Kong, and Macau; and license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, chronic constipation, and other GI conditions in Japan.

For more Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) news posted briefly go to: Nasdaq.com, Seekingalpha.com, Businesswire.com, Seekingalpha.com or Seekingalpha.com. The titles are as follows: “Health Care Sector Update for 03/22/2019: IRWD,IMMP,CNAT – Nasdaq” posted on March 22, 2019, “Ironwood completes Cyclerion spin-off – Seeking Alpha” on April 01, 2019, “Ironwood Pharmaceuticals to Present at Barclays Global Healthcare Conference – Business Wire” with a publish date: March 07, 2019, “Ironwood Pharmaceuticals beats by $0.16, beats on revenue – Seeking Alpha” and the last “Ironwood Pharmaceuticals Q4 2018 Earnings Preview – Seeking Alpha” with publication date: February 12, 2019.